%0 Journal Article
%T Evaluation of Guideline Line-Care Approach to the Treatment of Chronic Inducible Urticaria.
%A Sánchez J
%A Caraballo D
%A Amaya D
%J J Allergy Clin Immunol Pract
%V 12
%N 8
%D 2024 Aug 16
%M 38761861
暂无%R 10.1016/j.jaip.2024.05.011
%X <B>BACKGROUND: </B>Chronic inducible urticaria (CIndU) management often follows chronic spontaneous urticaria (CSU) guidelines, but a step-by-step evaluation of their effectiveness in CIndU is lacking.<BR><B>OBJECTIVE: </B>To assess the clinical impact of adapting CSU international guidelines for CIndU management.<BR><B>METHODS: </B>We conducted a prospective cohort study involving patients diagnosed with CIndU based on challenge tests and a Urticaria Control Test (UCT) score of ≤11 points. Following the guidelines, a stepwise approach was used: avoidance measures, antihistamines, omalizumab, and cyclosporine. Treatment steps were added based on individual response, with control defined as UCT ≥12 points. Pharmacological steps were evaluated for at least 1 month, with the next step initiated in case of a UCT score ≤11 points.<BR><B>RESULTS: </B>We enrolled 194 patients with CIndU. Of them, 134 patients had CIndU with concomitant CSU and 60 had CIndU only. Following the step-by-step approach outlined in the guidelines, a total of 159 (81.9%) patients reach a UCT ≥12 points, with avoidance measures 23 (11.8%) patients, antihistamines 84 (43.2%), omalizumab 35 (18%), and cyclosporine 17 (8.7%).<BR><B>CONCLUSIONS: </B>This study supports the use of a stepwise approach based on CSU guidelines for CIndU management. However, a significant proportion of patients, particularly those with CIndU only, did not achieve adequate control. This highlights the heterogeneity within CIndU and the need for further research to develop new therapies for patients with CIndU who remain uncontrolled.